Allergy Therapeutics plc (LON:AGY)‘s stock had its “buy” rating reiterated by investment analysts at Numis Securities Ltd in a research note issued on Tuesday. They presently have a GBX 37 ($0.48) price objective on the stock. Numis Securities Ltd’s target price would indicate a potential upside of 92.21% from the stock’s previous close.

A number of other analysts have also issued reports on AGY. Panmure Gordon reaffirmed a “buy” rating and issued a GBX 53 ($0.69) target price on shares of Allergy Therapeutics plc in a report on Friday, June 10th. Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 72 ($0.94) target price on shares of Allergy Therapeutics plc in a report on Friday, July 8th.

Shares of Allergy Therapeutics plc (LON:AGY) opened at 19.25 on Tuesday. Allergy Therapeutics plc has a 12 month low of GBX 17.25 and a 12 month high of GBX 34.82. The firm’s market capitalization is GBX 113.56 billion. The firm has a 50-day moving average price of GBX 18.69 and a 200 day moving average price of GBX 22.43.

In other news, insider Nicolas Wykeman acquired 150,000 shares of the firm’s stock in a transaction dated Tuesday, September 27th. The shares were bought at an average price of GBX 18 ($0.23) per share, with a total value of £27,000 ($35,243.44).

Allergy Therapeutics plc Company Profile

Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.

Receive News & Stock Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related stocks with our FREE daily email newsletter.